Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma

NCT07639983 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Muscle-Invasive Bladder Cancer (MIBC)
Urinary Bladder Cancer

Interventions

DRUG: Trastuzumab Rezetecan plus Camrelizumab

Sponsor

Sheng Tai